Dupilumab (Dupixent®) – first-in-class, PBS-listed IL-4 receptor alpha biologic (targeting IL-4 and IL-13) for uncontrolled severe asthma
An estimated 2.7 million Australians have asthma and in 3–10% of cases, this is considered to be severe.1,2 From 1...
